About Us

Corporate Information

Life Technologies is a global biotechnology tools company providing premier systems, consumables, and services for scientific researchers around the world.

Life Technologies customers conduct their research across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st-century forensics.

Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems, Inc. in November of 2008, and Life Technologies continues to serve its customers under those two well-known brands. Invitrogen is the premier provider of reagents and consumables that are usable across multiple platforms, while Applied Biosystems remains the top provider of systems-based, end-to-end solutions in areas such as PCR, genetic sequencing, and mass spectrometry.

With more than 50,000 products used by more than 75,000 customers around the globe, Life Technologies is advancing scientific research in areas like academic research, drug discovery and development, toxicology and forensics, disease diagnostics, clinical cell therapy and regenerative medicine, and biologics manufacturing.

Life Technologies is a strong proponent of global corporate social responsibility. Through the Life Technologies Foundation, our company has donated millions of dollars to help demystify the world of science, empower today’s children to become tomorrow’s scientific leaders, and deepen society’s appreciation of science.

The company is also proud of its global citizenship and efforts to reduce its environmental impact; we have reduced our CO2 emissions by 36% since 2006 and energy consumption by 32% since 2004. Life Technologies is a member of FTSE4Good Index Series and the Dow Jones Sustainability Index, where it was Biotechnology Sector Leader in 2008.

Company Highlights

  • Life Technologies' brands are found in more than 90% of research laboratories in the United States.
  • Life Technologies is the leading supplier of stem cell research consumables and products.
  • Life Technologies spends approximately $300 million per year in research and development.

News

  • TGen Study

    LifeTechnologies Corporation announced that it is collaborating with the Translational Genomics Research Institute (TGen) and US Oncology to sequence the genomes of 14 patients afflicted with triple negative breast cancer whose tumors have progressed despite multiple other therapies. The goal of this first-of-its-kind research collaboration is to demonstrate whether genomic sequencing of cancer tissue can provide clues for treatment strategies for these individuals.

    Read All Close
  • SMS Technology

    Life Technologies Corporation announced early stage results from its single molecule sequencing (SMS) technology. The technology promises to combine virtually unlimited continuous long read lengths with unmatched accuracy to deliver targeted genomic sequence data in a matter of hours, paving the way for sequencing to become a commonplace tool in research laboratories and clinical settings worldwide.

    Read All Close
  • SOLiD PI ANNOUNCED

    Life Technologies Corporation today announced plans for the Applied Biosystems SOLiD(TM) PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide. Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.

    Read All Close

Life (Common Stock)